Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine.

Wyatt NJ. et al, (2024), BMJ Open, 14

Altered DNA methylation within DNMT3A, AHRR, LTA/TNF loci mediates the effect of smoking on inflammatory bowel disease.

Zhang H. et al, (2024), Nat Commun, 15

P802 Relationships between validated clinical, endoscopic and histological indices in ulcerative colitis

Walsh AJ. et al, (2023), Journal of Crohn's and Colitis

Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.

Wong S-Y. et al, (2023), Inflamm Bowel Dis, 29, 1693 - 1705

Dietary Inflammatory Indices Are Not Associated With Inflammatory Bowel Disease Incidence and Progression.

Wellens J. et al, (2023), Inflamm Bowel Dis

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.

Barnes E. et al, (2023), Nat Med, 29, 1760 - 1774

Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation-authors' reply.

Chen J. et al, (2023), Aliment Pharmacol Ther, 57, 1034 - 1035

Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases-moving towards causal associations. Authors' reply.

Chen J. et al, (2023), Aliment Pharmacol Ther, 57, 1048 - 1049

Intake of Ultra-processed Foods Is Associated with an Increased Risk of Crohn's Disease: A Cross-sectional and Prospective Analysis of 187 154 Participants in the UK Biobank.

Chen J. et al, (2023), J Crohns Colitis, 17, 535 - 552

Defining Interactions Between the Genome, Epigenome, and the Environment in Inflammatory Bowel Disease: Progress and Prospects.

Noble AJ. et al, (2023), Gastroenterology

Defining gene-lifestyle interactions in inflammatory bowel disease: progress towards understanding disease pathogenesis.

Zhao J. et al, (2023), Gut

Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research

Alexander JL. et al, (2023), Gut

The Contribution of Genetic Risk and Lifestyle Factors in the Development of Adult-Onset Inflammatory Bowel Disease: A Prospective Cohort Study.

Sun Y. et al, (2023), Am J Gastroenterol

Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease

Shubhakar A. et al, (2023), Journal of Crohn's and Colitis

Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study.

Chen J. et al, (2023), Aliment Pharmacol Ther

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.

Louis E. et al, (2023), Lancet Gastroenterol Hepatol

Epigenetic alterations in DNMT3A, AHRR and LTA/TNF loci mediate the effect of smoking on inflammatory bowel disease susceptibility

Li X. et al, (2023), GUT, 72, A35 - A35

EPIGENOME-WIDE PERIPHERAL BLOOD DNA METHYLATION PROFILES ACCURATELY PREDICT ENDOSCOPIC- AND CLINICAL RESPONSE AND REMAIN HIGHLY STABLE DURING INDUCTION AND MAINTENANCE TREATMENT WITH ADALIMUMAB, VEDOLIZUMAB AND USTEKINUMAB IN CROHN'S DISEASE PATIENTS

Joustra V. et al, (2023), GASTROENTEROLOGY, 164, S101 - S101

Generalised urticaria and angioedema complicating switch back from subcutaneous to intravenous vedolizumab therapy.

Chauhan D. et al, (2023), Frontline Gastroenterol, 14, 432 - 434

HIGHLY STABLE EPIGENOME-WIDE PERIPHERAL BLOOD DNA METHYLATION SIGNATURES ACCURATELY PREDICT RESPONSE TO ADALIMUMAB, VEDOLIZUMAB AND USTEKINUMAB IN CROHN'S DISEASE PATIENTS

Joustra V. et al, (2023), GUT, 72, A36 - A38

Load More

1
2
3
4
5
6

Include forthcoming?